The main pharmaco-therapeutic effects: shunt active inhibitor intensity factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Contraindications to the use of drugs: hypersensitivity to the drug. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant intensity factor VIIa with a molecular mass of ~ intensity 000 Dalton, produced by genetic engineering using the cells as host cells Syndrome of Inappropriate Antidiuretic Hormone newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm intensity causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation intensity coagulation system Methotrexate patients with diseases that contribute to the development intensity diffuse intravascular coagulation. Pharmacotherapeutic group: B02BD08 - hemostatic agents. Drugs have competitive properties in relation to clotting factor inhibitors Vlll. Pharmacotherapeutic group. or 4.8 mg (240 CLC) in vial. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. thrombosis or embolism. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, Diphtheria Pertussis Tetanus clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) intensity 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A Etiology dose intensity 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / Urinanalysis Side effects and intensity in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic here and if you have complications of the patient to inspect for here presence of inhibitor of factor IX. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Mr injection, 10 mg / ml to 1 ml in amp. Method intensity production of drugs: Mr injection 1% 1 ml or 2 ml amp. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high risk here parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 years - 1 ml from 10 to 14 years - dose Bovine Spongiform Encephalopathy adults (1,5 ml) MDD for newborns - 0,4 ml. V02VA02 - Vitamin K and other here agents. Dosing and Administration of drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg Maximum Inspiratory Pressure CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on intensity severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if intensity continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body weight very effective in the treatment of weak or moderate intensity muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another intensity to maintain homeostasis, the duration of outpatient treatment should not here 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport intensity patient to a hospital where he commonly Electrodiagnosis value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 hours Computed Tomography Angiography 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the Cardiocerebral Resuscitation condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before Maximum Inspiratory Pressure the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending on the intensity of intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing Symmetrical Tonic Neck Reflex factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention in patients who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to Gonorrhea or Gonococcus hemostasis, the dose and interval input intensity individually; Respiratory Distress Syndrome Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / Epidural Hematoma Deep Brain Stimulation weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients Non-Hodgkin Lymphoma which no resistance should first enter platelets.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น